Skip to main content

Table 5 Patient outcomes according to the value of the initial and maximal trough concentration (Cmin)

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Outcomes No. of patients with initial Cmin No. of patients with maximal Cmin
< 20 μg/mL ≥20 μg/mL P-value < 20 μg/mL ≥20 μg/mL P-value
Early clinical response (n = 76) 23/37 (62.2%) 31/39 (79.5%) 0.096
Clinical success at the end of therapy (n = 76) 25/37 (67.6%) 30/39 (76.9%) 0.362 22/33 (66.7%) 33/43 (76.7%) 0.330
Microbiological success (n = 68) 22/33 (66.7%) 25/35 (71.4%) 0.671 20/31 (64.5%) 27/37 (73.0%) 0.452
28 days mortality (n = 76) 5/37 (13.5%) 2/39 (5.1%) 0.256 5/33 (15.2%) 2/43 (4.7%) 0.229
  1. Eight patients in whom culture results after the start of therapy were not obtained were excluded from the microbiological success analysis